摘要
selumetinib(商品名:Koselugo^■)是一种口服、强效、选择性MEK1/2激酶抑制剂,也是首个获美国FDA批准的治疗小儿1型神经纤维瘤病(NF1)相关的症状性、不能手术的丛状神经纤维瘤(PN)的药物。本文对selumetinib的作用机制、药动学、临床研究及安全性等进行综述,为临床治疗和深入研究提供参考。
Selumetinib (Koselugo^■) is an orally administered,potent and selective kinase inhibitor of MEK 1/2.It is the first drug approved by the FDA for the treatment of pediatric patients with neurofibromatosis type1 (NF1) who have symptomatic,inoperable plexiform neurofibromas (PN).This article reviews the mechanism,pharmacokinetics,clinical research and safety of selumetinib to provide a reference for clinical treatment and further research.
作者
倪文骐
刘晓盈
朱峰
NI Wen-qi;LIU Xiao-ying;ZHU Feng(Health Service Department of the Guard Bureau of the Joint Staff Department of Chinese PLA,Beijing 100017,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2020年第22期2557-2560,共4页
Chinese Journal of New Drugs
